This is the question behind most retatrutide searches, so let's handle it honestly: this site cannot answer it for you — only a clinician who knows your health can. What we can do is lay out the facts that conversation needs, because the worst version of this decision is one made on headline numbers and guessed timelines.
Nothing here is medical advice, and nothing here should be read as a reason to delay care you need. If weight is affecting your health now, that's a reason to see a clinician now.
The timeline reality
The pull of waiting comes from TRIUMPH-1's results — 28.3% average weight loss at 80 weeks on the top dose. [2] The cost of waiting comes from the calendar:
- The U.S. FDA submission is planned for Q1 2027 — and that date already moved once, from "by end of 2026," to finish the manufacturing-quality package. [1]
- FDA review happens after submission and takes time; there is no approval date, and any date you see is a projection.
- Launch, supply and insurance coverage come after that.
Add it up and "waiting for retatrutide" plausibly means years of untreated time — against a backdrop where approved medications produce 15–22% average weight loss in their own trials today [3], and where weight's effects on blood pressure, glucose, joints and sleep don't pause while you wait. Our availability scenarios walk through the projected timeline in detail.
What starting now actually forecloses: less than you'd think
The implicit fear in "should I wait" is that starting semaglutide or tirzepatide now somehow uses up your shot at retatrutide. Three facts for that conversation:
- There is no switching data yet. Retatrutide's trials enrolled people not already on these medications, so no one can yet tell you what tirzepatide-to-retatrutide switching looks like. That's an open question for the approval era — not a documented penalty for starting now.
- Response is individual. Trial averages are averages. Some people do extremely well on today's drugs — tirzepatide averaged 20.2% versus semaglutide's 13.7% in the SURMOUNT-5 head-to-head [3] — and a strong response to an available drug changes the math on chasing a stronger one.
- The head-to-head that matters is coming. TRIUMPH-5, retatrutide versus tirzepatide directly, is expected to complete around December 2026 (Projected, third-party estimate). [4] Until it reads out, every retatrutide-vs-tirzepatide comparison is cross-trial — see our comparison for why that caveat matters.
A third option: trials
If what draws you to retatrutide is retatrutide itself, remember the one way to be on it now is a clinical trial — monitored, free study drug, labs included. [5] Enrollment windows and eligibility vary; the trials hub shows registered studies and U.S. site locations. For specific medical situations where a trial isn't possible, there's also Lilly's expanded access program, which your physician would apply to.
How to have the conversation
Bring these to a clinician — ideally one with real weight-management credentials (how to choose one):
- "Given my health right now, what does a year of waiting cost me?"
- "Which approved option fits me best, and what response would we consider a success?"
- "Am I plausibly eligible for a retatrutide trial — and is that worth pursuing?"
- "If retatrutide is approved later (projected), how would we think about switching at that point?"
A good clinician will have opinions on all four. The decision that comes out of that conversation — start now, pursue a trial, or something else — will be yours and theirs, made on your facts.
Find weight-loss providers near you, and for every change in retatrutide's status between now and the FDA's decision, the approval tracker and email updates have you covered.